Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 128.54
LCI's Cash to Debt is ranked higher than
88% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. LCI: 128.54 )
LCI' s 10-Year Cash to Debt Range
Min: 0   Max: 128.54
Current: 128.54

0
128.54
Equity to Asset 0.86
LCI's Equity to Asset is ranked higher than
92% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. LCI: 0.86 )
LCI' s 10-Year Equity to Asset Range
Min: -1.05   Max: 0.86
Current: 0.86

-1.05
0.86
Interest Coverage 677.61
LCI's Interest Coverage is ranked higher than
73% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 97.33 vs. LCI: 677.61 )
LCI' s 10-Year Interest Coverage Range
Min: 1.15   Max: 677.61
Current: 677.61

1.15
677.61
F-Score: 7
Z-Score: 24.42
M-Score: -1.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 32.18
LCI's Operating margin (%) is ranked higher than
97% of the 787 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.15 vs. LCI: 32.18 )
LCI' s 10-Year Operating margin (%) Range
Min: -119.46   Max: 46.27
Current: 32.18

-119.46
46.27
Net-margin (%) 20.86
LCI's Net-margin (%) is ranked higher than
95% of the 787 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. LCI: 20.86 )
LCI' s 10-Year Net-margin (%) Range
Min: -73   Max: 28.64
Current: 20.86

-73
28.64
ROE (%) 26.62
LCI's ROE (%) is ranked higher than
97% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.47 vs. LCI: 26.62 )
LCI' s 10-Year ROE (%) Range
Min: -38.23   Max: 117.18
Current: 26.62

-38.23
117.18
ROA (%) 22.58
LCI's ROA (%) is ranked higher than
98% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. LCI: 22.58 )
LCI' s 10-Year ROA (%) Range
Min: -28.9   Max: 50.98
Current: 22.58

-28.9
50.98
ROC (Joel Greenblatt) (%) 79.81
LCI's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.76 vs. LCI: 79.81 )
LCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -162.82   Max: 107.31
Current: 79.81

-162.82
107.31
Revenue Growth (%) 24.90
LCI's Revenue Growth (%) is ranked higher than
89% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. LCI: 24.90 )
LCI' s 10-Year Revenue Growth (%) Range
Min: -3.6   Max: 48.4
Current: 24.9

-3.6
48.4
EBITDA Growth (%) 152.30
LCI's EBITDA Growth (%) is ranked higher than
99% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. LCI: 152.30 )
LCI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 152.3
Current: 152.3

0
152.3
» LCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

LCI Guru Trades in Q3 2013

Steven Cohen 16,217 sh (New)
Jim Simons 198,300 sh (+7.31%)
» More
Q4 2013

LCI Guru Trades in Q4 2013

Paul Tudor Jones 7,818 sh (New)
Jim Simons 188,400 sh (-4.99%)
Steven Cohen 7,348 sh (-54.69%)
» More
Q1 2014

LCI Guru Trades in Q1 2014

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 111,800 sh (-40.66%)
» More
Q2 2014

LCI Guru Trades in Q2 2014

Chuck Royce 338,400 sh (New)
Joel Greenblatt 35,709 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with LCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.02%$29.62 - $49.76 $ 49.326%35709
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 32.30
LCI's P/E(ttm) is ranked higher than
77% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.30 vs. LCI: 32.30 )
LCI' s 10-Year P/E(ttm) Range
Min: 13.82   Max: 185.79
Current: 32.3

13.82
185.79
P/B 5.90
LCI's P/B is ranked lower than
52% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. LCI: 5.90 )
LCI' s 10-Year P/B Range
Min: 0.61   Max: 12.64
Current: 5.9

0.61
12.64
P/S 6.30
LCI's P/S is ranked higher than
55% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. LCI: 6.30 )
LCI' s 10-Year P/S Range
Min: 0.49   Max: 7.09
Current: 6.3

0.49
7.09
PFCF 109.30
LCI's PFCF is ranked higher than
75% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 109.30 )
LCI' s 10-Year PFCF Range
Min: 3.21   Max: 342.5
Current: 109.3

3.21
342.5
EV-to-EBIT 18.14
LCI's EV-to-EBIT is ranked higher than
86% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.86 vs. LCI: 18.14 )
LCI' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 687.5
Current: 18.14

6.9
687.5
PEG 0.58
LCI's PEG is ranked higher than
98% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 0.58 )
LCI' s 10-Year PEG Range
Min: 0.2   Max: 77.25
Current: 0.58

0.2
77.25
Shiller P/E 101.80
LCI's Shiller P/E is ranked higher than
66% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 96.41 vs. LCI: 101.80 )
LCI' s 10-Year Shiller P/E Range
Min: 21.37   Max: 358
Current: 101.8

21.37
358
Current Ratio 5.65
LCI's Current Ratio is ranked higher than
90% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. LCI: 5.65 )
LCI' s 10-Year Current Ratio Range
Min: 0.96   Max: 5.65
Current: 5.65

0.96
5.65
Quick Ratio 4.70
LCI's Quick Ratio is ranked higher than
89% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. LCI: 4.70 )
LCI' s 10-Year Quick Ratio Range
Min: 0.39   Max: 4.7
Current: 4.7

0.39
4.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.76
LCI's Price/Net Cash is ranked higher than
89% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 17.76 )
LCI' s 10-Year Price/Net Cash Range
Min: 17.61   Max: 28.36
Current: 17.76

17.61
28.36
Price/Net Current Asset Value 8.46
LCI's Price/Net Current Asset Value is ranked higher than
90% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 8.46 )
LCI' s 10-Year Price/Net Current Asset Value Range
Min: 3.82   Max: 93.88
Current: 8.46

3.82
93.88
Price/Tangible Book 5.92
LCI's Price/Tangible Book is ranked higher than
66% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.93 vs. LCI: 5.92 )
LCI' s 10-Year Price/Tangible Book Range
Min: 1.12   Max: 21.7
Current: 5.92

1.12
21.7
Price/DCF (Projected) 5.77
LCI's Price/DCF (Projected) is ranked higher than
77% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.00 vs. LCI: 5.77 )
LCI' s 10-Year Price/DCF (Projected) Range
Min: 0.81   Max: 5.72
Current: 5.77

0.81
5.72
Price/Median PS Value 3.93
LCI's Price/Median PS Value is ranked higher than
54% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. LCI: 3.93 )
LCI' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 6.93
Current: 3.93

0.45
6.93
Price/Peter Lynch Fair Value 1.64
LCI's Price/Peter Lynch Fair Value is ranked higher than
92% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 1.64 )
LCI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.68   Max: 1.96
Current: 1.64

0.68
1.96
Price/Graham Number 2.82
LCI's Price/Graham Number is ranked higher than
78% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.08 vs. LCI: 2.82 )
LCI' s 10-Year Price/Graham Number Range
Min: 0.94   Max: 6.23
Current: 2.82

0.94
6.23
Earnings Yield (Greenblatt) 5.50
LCI's Earnings Yield (Greenblatt) is ranked higher than
77% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. LCI: 5.50 )
LCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 14.4
Current: 5.5

0.1
14.4
Forward Rate of Return (Yacktman) 19.53
LCI's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. LCI: 19.53 )
LCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.9   Max: 88.6
Current: 19.53

-2.9
88.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:LN5.Germany
Lannett Company, Inc. was incorporated in 1942 under the laws of the Commonwealth of Pennsylvania, and reincorporated in 1991 as a Delaware corporation. The Company develops, manufactures, markets and distributes generic versions of branded pharmaceutical products. All of the products are currently manufactured and sold are prescription products. The Company's products containing Levo are produced and marketed with 12 varying potencies. In addition to generic Levo tablets, it also market and distribute Unithroid tablets, a branded version of Levo, which is produced and marketed with 11 varying potencies. Both generic Levo tablets and Unithroid tablets are manufactured by JSP. Lannett began buying generic Levo from JSP and selling it to its customers in April 2003. Levo tablets are used to treat hypothyroidism and other thyroid disorders. Levo remains the most prescribed drugs in the U.S. and is used by over 13 million patients of various ages and demographic backgrounds. In distribution of these products, the Company competes with two branded Levo products-Abbott Laboratories' Synthroid(r) and Monarch Pharmaceutical's Levoxyl(r)- as well as generic products from Mylan and Sandoz. Digoxin tablets are produced and marketed with two different potencies, 0.125mg and 0.25mg per tablet. This product is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in September 2002. Digoxin tablets are used to treat congestive heart failure in patients of various ages and demographic backgrounds. The Company distributes two products containing Butalbital. Lannett has manufactured and sold one of the products, Butalbital with Aspirin and Caffeine capsules, for more than nine years. The other Butalbital product, Butalbital with Aspirin, Caffeine and Codeine Phosphate capsules, is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in December 2002. Both Butalbital products, which are in orally administered capsule dosage forms, are prescribed to treat tension headaches caused by contractions of the muscles in the neck and shoulder area and migraine. Primidone tablets are produced and marketed with two different potencies, 50mg and 250mg tablets. Lannett has developed and manufacture Primidone tablets and began selling Primidone 50mg tablets in June 2001. In addition, the Company has been manufacturing and selling Primidone 250mg tablets for more than seven years. Both Primidone products, which are in orally administered tablet dosage forms, are prescribed to treat convulsion and seizures in epileptic patients of all ages and demographic backgrounds. Lannett sell its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations
» More Articles for LCI

Headlines

Articles On GuruFocus.com
comment on LCI Nov 19 2012 
comment on LCI Nov 13 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 23 2012 
comment on LCI Jan 23 2012 
Lannett Company Inc Reports Operating Results (10-Q) Nov 12 2010 
Lannett Company Inc Reports Operating Results (10-K) Sep 24 2010 
View on LCI May 17 2010 
Lannett Company Inc Reports Operating Results (10-Q) May 13 2010 


More From Other Websites
Five Leading Stocks Stage Breakouts As Market Rallies Oct 23 2014
LANNETT CO INC Files SEC form 8-K, Results of Operations and Financial Condition Oct 23 2014
Major Indexes Close Higher; Lannett Breaks Out Oct 23 2014
Why Lannett (LCI) Stock Is Surging Today Oct 23 2014
Nascent Rally Gains Traction; Caterpillar, 3M Boost Dow Oct 23 2014
Stocks Jump To Early Gains; Lannett, Alexion Break Out Oct 23 2014
7:56 am Lannett issues prelim Q1 sales of ~$93 mln vs $90.2 mln Capital IQ Consensus, sees EPS of... Oct 23 2014
Lannett Announces Preliminary Fiscal 2015 First Quarter Net Sales of Approximately $93 Million, EPS... Oct 23 2014
Illumina Breaks Out Of Double-Bottom Base Oct 22 2014
Pharmacyclics Up on Label Expansion Efforts for Imbruvica Oct 22 2014
IBD 50: Five Stocks Forming Intriguing Chart Patterns Oct 17 2014
EQUITY ALERT: Rosen Law Firm Reminds Lannett Company, Inc. Investors of Important October 27, 2014... Oct 14 2014
Stocks Close Mixed, Surrendering Some Early Gains Oct 14 2014
Lannett (LCI) Stock: Moving Average Crossover Alert Oct 10 2014
Generics Firms Step Up Their Game In Branded Drugs Oct 06 2014
Stocks Improve In Late Trade; Netflix Eyes Third Gain Oct 06 2014
Ardelyx (ARDX) Worth Watching: Stock Moves 16% Higher Oct 06 2014
NanoViricides, Inc. (NNVC) in Focus: Stock Jumps 9.9% Oct 06 2014
Esperion Therapeutics (ESPR) in Focus: Stock Jumps 5.1% Oct 06 2014
Durata Therapeutics, Inc. (DRTX) Surges: Stock Rises 17.3% Oct 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK